University of Pennsylvania researchers have developed a powerful new investigative tool to reveal how proteins work inside ...

Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail the growth of several cancer types. A review paper published last year in European ...

Colorectal cancer is the third most diagnosed type of cancer worldwide. Up to 80% of the cases are related to environmental ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Burkitt lymphoma, a cancer that impacts a subset of immune cells called B cells, develops most often in children and young adults.  Patients with Burk | Cancer ...

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

RNA sequencing expression analyses indicated that Parabilis's ERG degrader downregulated Myc target genes. Parabilis's ERG degrader uses Helicon technology to bind directly to the ERG protein and, ...

The mitochondrial unfolded protein response (UPR mt ... They also identified c-Myc as a key factor in the activation of UPR mt —overexpression of c-Myc significantly increased the expression ...